Pregnancy: Data available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity. Since systemic exposure to ciprofloxacin will be very low no effects are anticipated on the foetus. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from fluocinolone acetonide.
Before administering the medicine, an assessment should be made on the benefits of the treatment outweightening the possible risk.
Breastfeeding: Ciprofloxacin is excreted in breast milk. Since systemic exposure to ciprofloxacin will be very low no effects are anticipated on the children that are breastfeeding.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk.
Caution should be exercised when Cetraxal Plus is administered to a nursing woman.
Fertility: No animal studies have been performed to evaluate the effect on fertility of Cetraxal Plus.